-+ 0.00%
-+ 0.00%
-+ 0.00%

Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026

PUBT·04/17/2026 13:05:23
Listen to the news
Acadia presents Phase 4 LOTUS real-world DAYBUE data in Rett syndrome at AAN 2026
  • Acadia Pharmaceuticals scheduled multiple data presentations for April 18-22, 2026 at American Academy of Neurology annual meeting in Chicago.
  • New real-world analysis from ongoing Phase 4 LOTUS study will be presented in future, assessing DAYBUE use in adults with Rett syndrome in routine clinical practice.
  • Exploratory analyses due at meeting will examine differences in response patterns to NUPLAZID in Parkinson’s disease psychosis, including impact of baseline sleep disturbances.
  • Translational and pharmacokinetic research to be debuted supports continued development of ACP-711 for essential tremor, including work intended to inform dose selection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260417097485) on April 17, 2026, and is solely responsible for the information contained therein.